{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:12:49Z","timestamp":1789053169753,"version":"build-2803163510"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Steatotic liver disease related to metabolic dysfunction is the most common cause of chronic liver disease globally. The spectrum of this condition includes steatosis and steatohepatitis and was previously referred to as non-alcoholic fatty liver disease (NAFLD) but has been renamed as metabolic dysfunction-associated fatty liver disease (MAFLD) and more recently as metabolic dysfunction-associated steatotic liver disease (MASLD). Angiopoietin-like protein 8 (ANGPTL8), also known as betatrophin or lipasin, regulates triglycerides and has emerged as a potential novel biomarker for steatosis\/steatohepatitis. Therefore, this systematic review aimed to identify and synthesize the evidence on the possible association of circulating ANGPTL8 concentrations with NAFLD, MAFLD or MASLD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PubMed\/MEDLINE, Cochrane Library, EMBASE, and Web of Science were searched for studies published in English reporting circulating ANGPTL8 concentrations in adults with NAFLD or MAFLD or MASLD and controls. A meta-analysis was performed, reporting the standardized mean difference (SMD) of circulating ANGPTL8 concentrations between these two groups. Study quality and risk of bias were assessed using the NIH quality assessment tool and RoBANS 2, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 104 identified publications, eight studies were eligible for this systematic review, whilst seven were also eligible for meta-analysis (543 NAFLD or MAFLD cases <jats:italic>vs.<\/jats:italic> 352 controls). Circulating ANGPTL8 concentrations were significantly higher in patients with NAFLD or MAFLD compared with controls (SMD: 0.62, 95%CI: 0.28-0.97; p&amp;lt;0.001). Considerable heterogeneity was noted among these studies, with six studies having high risk of bias in at least one RoBANS 2 domain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These findings present up-to-date comprehensive evidence indicating that adults with steatotic liver disease related to metabolic dysfunction exhibit higher circulating ANGPTL8 concentrations compared with controls. Given the need for novel screening\/diagnostic biomarkers for steatosis\/steatohepatitis, as well for additional drug targets, large and prospective studies are required to confirm this association and explore its temporal direction, particularly under the new MASLD diagnosis\/term.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1574842","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:10:23Z","timestamp":1744258223000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Circulating angiopoietin-like protein 8 (ANGPTL8) and steatotic liver disease related to metabolic dysfunction: an updated systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Farah","family":"Abdelhameed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Lagojda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Kite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dallaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attia","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nwe Ni","family":"Than","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpal S.","family":"Randeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Kyrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-024-00574-z","article-title":"Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated steatotic liver disease (MASLD): A comprehensive review from NAFLD to MAFLD and MASLD","volume":"13","author":"Abdelhameed","year":"2024","journal-title":"Curr Obes Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3390\/metabo12111073","article-title":"Nonalcoholic fatty liver disease-A concise review of noninvasive tests and biomarkers","volume":"12","author":"Bassal","year":"2022","journal-title":"Metabolites"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10620-y","article-title":"Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification","volume":"18","author":"Ramirez-Mejia","year":"2024","journal-title":"Hepatol Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.05.008","article-title":"Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease","volume":"75","author":"Younes","year":"2021","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/hep.0000000000000843","article-title":"AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000845","article-title":"AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000001019","article-title":"Noninvasive assessment of liver fibrosis and portal hypertension","volume":"40","author":"Duarte-Rojo","year":"2024","journal-title":"Curr Opin Gastroenterol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000852","article-title":"Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline","volume":"81","author":"Duarte-Rojo","year":"2025","journal-title":"Hepatology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.21037\/tgh.2020.04.01","article-title":"Evolution of the liver biopsy and its future","volume":"6","author":"Jain","year":"2021","journal-title":"Transl Gastroenterol Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27739","article-title":"Role of the angiopoietin-like protein family in the progression of NAFLD","volume":"10","author":"Su","year":"2024","journal-title":"Heliyon"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4604-4","article-title":"Can targeting ANGPTL proteins improve glucose tolerance","volume":"61","author":"Davies","year":"2018","journal-title":"Diabetologia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12933-014-0133-8","article-title":"A dual role of lipasin (betatrophin) in lipid metabolism and glucose homeostasis: consensus and controversy","volume":"13","author":"Zhang","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2005.08.002","article-title":"Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy","volume":"11","author":"Oike","year":"2005","journal-title":"Trends Mol Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3109\/1061186X.2014.928715","article-title":"Angiopoietin-like proteins 3, 4 and 8: regulating lipid metabolism and providing new hope for metabolic syndrome","volume":"22","author":"Li","year":"2014","journal-title":"J Drug Targeting"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2010.07979.x","article-title":"Angiopoietin-like proteins: emerging targets for treatment of obesity and related metabolic diseases","volume":"278","author":"Kadomatsu","year":"2011","journal-title":"FEBS J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/livers3030031","article-title":"Challenges in the management of non-alcoholic fatty liver disease (NAFLD): towards a compassionate approach","volume":"3","author":"Shea","year":"2023","journal-title":"Livers-Basel"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.01.012","article-title":"Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclature","volume":"80","author":"Lonardo","year":"2024","journal-title":"J Hepatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4082\/kjfm.23.0034","article-title":"RoBANS 2: A revised risk of bias assessment tool for nonrandomized studies of interventions","volume":"44","author":"Seo","year":"2023","journal-title":"Korean J Fam Med"},{"key":"B24","doi-asserted-by":"crossref","unstructured":"Study Quality Assessmet Tools 2013\n          \n          \n          \n          2024","DOI":"10.1155\/2024\/9769363"},{"key":"B25","doi-asserted-by":"publisher","first-page":"igz036","DOI":"10.1093\/geroni\/igz036","article-title":"Effect size guidelines, sample size calculations, and statistical power in gerontology","volume":"3","author":"Brydges","year":"2019","journal-title":"Innov Aging"},{"key":"B26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.v1:2","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"Viechtbauer","year":"2010","journal-title":"Res Synth Methods"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/sim.v21:11","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"B30","volume-title":"dmetar: Companion R Package For The Guide \u2018Doing Meta-Analysis in R\u2019. R package version 0.1.0","author":"Harrer","year":"2019"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"B32","volume-title":"metaviz: forest plots, funnel plots, and visual funnel plot inference for meta-analysis","author":"Kossmeier","year":"2020"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1177\/1745691614553988","article-title":"p-curve and effect size: correcting for publication bias using only significant results","volume":"9","author":"Simonsohn","year":"2014","journal-title":"Perspect Psychol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1037\/a0033242","article-title":"P-curve: a key to the file-drawer","volume":"143","author":"Simonsohn","year":"2014","journal-title":"J Exp Psychol Gen"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1037\/xge0000104","article-title":"Better P-curves: Making P-curve analysis more robust to errors, fraud, and ambitious P-hacking, a Reply to Ulrich and Miller (2015)","volume":"144","author":"Simonsohn","year":"2015","journal-title":"J Exp Psychol Gen"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170758","article-title":"Relationship of serum betatrophin with nonalcoholic fatty liver in a chinese population","volume":"12","author":"Hu","year":"2017","journal-title":"PloS One"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-102950","article-title":"ANGPTL8 (Betatrophin) is expressed in visceral adipose tissue and relates to human hepatic steatosis in two independent clinical collectives","volume":"49","author":"von Loeffelholz","year":"2017","journal-title":"Horm Metab Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3390\/metabo11070425","article-title":"Betatrophin levels are related to the early histological findings in nonalcoholic fatty liver disease","volume":"11","author":"Sonmez","year":"2021","journal-title":"Metabolites"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.2018.9.issue-4","article-title":"Angiopoietin-like protein 8\/betatrophin correlates with hepatocellular lipid content independent of insulin resistance in non-alcoholic fatty liver disease patients","volume":"9","author":"Hong","year":"2018","journal-title":"J Diabetes Investig"},{"key":"B40","doi-asserted-by":"publisher","first-page":"24013","DOI":"10.1038\/srep24013","article-title":"Association between betatrophin\/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies","volume":"6","author":"Lee","year":"2016","journal-title":"Sci Rep"},{"key":"B41","article-title":"Serum betatrophin level increased in subjects with non-alcoholic fatty liver disease","volume":"9","author":"Zhu","year":"2016","journal-title":"Int J Of Eclinical And Exp Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v15.i3.418","article-title":"Predictive value of angiopoietin-like protein 8 in metabolic dysfunction-associated fatty liver disease and its progression: A case-control study","volume":"15","author":"Gan","year":"2024","journal-title":"World J Diabetes"},{"key":"B43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/MEG.0000000000000502","article-title":"Serum beta-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis","volume":"28","author":"Cengiz","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12944-021-01481-1","article-title":"Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis","volume":"20","author":"Ke","year":"2021","journal-title":"Lipids Health Dis"},{"key":"B45","article-title":"Establishment and analysis of a nonalcoholic fatty liver disease nomogram prediction model based on serum Betatrophin levels","volume":"16","author":"Gao","year":"2019","journal-title":"China Med Herald"},{"key":"B46","article-title":"Application value of serum Betatrophin levels in assessing the severity of non-alcoholic fatty liver disease","volume":"24","author":"Long","year":"2019","journal-title":"Chin Hepatol"},{"key":"B47","article-title":"The value of novel insulin hormone levelss in the clinical diagnosis of non-alcoholic fatty liver disease","volume":"27","author":"Yang","year":"2017","journal-title":"Chin J Integrated Trad Western Med Liver Dis"},{"key":"B48","article-title":"Changes and significance of serum ALT, AST and betatrophin levels in patients with nonalcoholic fatty liver disease","volume":"5","author":"Zhang","year":"2021","journal-title":"Mod Med Health Res"},{"key":"B49","article-title":"Study on the effect of \u03b2-trophin on in the pathogenesis of non-alcoholic fatty liver disease","volume":"31","author":"Zhang","year":"2018","journal-title":"Med J West China"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3093","article-title":"Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications","volume":"98","author":"Targher","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i48.5240","article-title":"Impact of liver diseases on the development of type 2 diabetes mellitus","volume":"17","author":"Hsieh","year":"2011","journal-title":"World J Gastroenterol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12200","article-title":"Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up","volume":"33","author":"Zelber-Sagi","year":"2013","journal-title":"Liver Int"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0602","article-title":"Increased circulating levels of betatrophin in newly diagnosed type 2 diabetic patients","volume":"37","author":"Hu","year":"2014","journal-title":"Diabetes Care"},{"key":"B54","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1038\/srep05013","article-title":"Elevated circulating lipasin\/betatrophin in human type 2 diabetes and obesity","volume":"4","author":"Fu","year":"2014","journal-title":"Sci Rep"},{"key":"B55","doi-asserted-by":"publisher","first-page":"101140","DOI":"10.1016\/j.plipres.2021.101140","article-title":"An updated ANGPTL3-4-8 model as a mechanism of triglyceride partitioning between fat and oxidative tissues","volume":"85","author":"Zhang","year":"2022","journal-title":"Prog Lipid Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"101067","DOI":"10.1016\/j.plipres.2020.101067","article-title":"The multi-faces of Angptl8 in health and disease: Novel functions beyond lipoprotein lipase modulation","volume":"80","author":"Abu-Farha","year":"2020","journal-title":"Prog Lipid Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2014.06.006","article-title":"Liver enzymes and risk of cardiovascular disease in the general population: a meta-analysis of prospective cohort studies","volume":"236","author":"Kunutsor","year":"2014","journal-title":"Atherosclerosis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.2019.23.issue-8","article-title":"Angiopoietin-like protein 8 expression and association with extracellular matrix metabolism and inflammation during intervertebral disc degeneration","volume":"23","author":"Liao","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1113811","DOI":"10.1155\/2022\/1113811","article-title":"Angiopoietin-like 8 in gestational diabetes mellitus: reduced levels in third trimester maternal serum and placenta, increased levels in cord blood serum","volume":"2022","author":"Yuan","year":"2022","journal-title":"Int J Endocrinol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"154921","DOI":"10.1016\/j.metabol.2021.154921","article-title":"Angiopoietin-like protein 8 (betatrophin) inhibits hepatic gluconeogenesis through PI3K\/Akt signaling pathway in diabetic mice","volume":"126","author":"Zhao","year":"2022","journal-title":"Metabolism"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1574842\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:10:27Z","timestamp":1744258227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1574842\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":60,"alternative-id":["10.3389\/fendo.2025.1574842"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1574842","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"article-number":"1574842"}}